Table 2. Relative risk of positive axillary nodes after NCT in patients with and without breast pCR (%).
| Characteristics | Breast pCR | Total | Axillary pCR | RR | 95% CI | P | |
|---|---|---|---|---|---|---|---|
| No | Yes | ||||||
| N0 | No | 321 | 139 [43] | 182 [57] | |||
| Yes | 85 | 9 [11] | 76 [89] | 6.45 | 3.12–13.32 | <0.01 | |
| N1 | No | 560 | 364 [65] | 196 [35] | |||
| Yes | 185 | 51 [28] | 134 [72] | 4.88 | 3.38–7.04 | <0.01 | |
| N2 | No | 386 | 297 [77] | 89 [23] | |||
| Yes | 138 | 51 [37] | 87 [63] | 5.69 | 3.74–8.66 | <0.01 | |
| N3 | No | 157 | 115 [73] | 42 [27] | |||
| Yes | 59 | 18 [31] | 41 [69] | 6.24 | 3.23–12.03 | <0.01 | |
| Total | No | 1,424 | 915 [64] | 509 [36] | |||
| Yes | 467 | 129 [28] | 338 [72] | 4.71 | 3.74–5.93 | <0.01 | |
| HR+HER2− | No | 696 | 519 [75] | 177 [25] | |||
| Yes | 121 | 51 [42] | 70 [58] | 4.02 | 2.70–6.00 | <0.01 | |
| HR+HER2+ | No | 298 | 174 [58] | 124 [42] | |||
| Yes | 122 | 29 [24] | 93 [76] | 4.50 | 2.79–7.25 | <0.01 | |
| HR−HER2+ | No | 204 | 99 [49] | 105 [51] | |||
| Yes | 106 | 21 [20] | 85 [80] | 3.82 | 2.20–6.62 | <0.01 | |
| TNBC | No | 216 | 119 [55] | 97 [45] | |||
| Yes | 119 | 27 [23] | 92 [77] | 4.18 | 2.52–6.93 | <0.01 | |
| Total | No | 1,414 | 911 [64] | 503 [36] | |||
| Yes | 468 | 128 [27] | 340 [73] | 4.81 | 3.82–6.06 | <0.01 | |
Adjusted RRN =5.49, 95% CI: 4.31–6.99, P<0.01; adjusted RRSubtype =4.13, 95% CI: 3.26–5.24, P<0.01; pCR, pathologic complete response; RR, relative risk; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; +, positive; −, negative.